Similarly, the specific modification of point mutations in epidermal growth factor receptor (EGFR) L858R-positive lung cancer by CRISPR/Cas9 resulted in robust attenuation of EGFR expression and cell proliferation. This evidence concerns the gene EGFR and lung cancer.